Literature DB >> 22075287

Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study.

Alessandro Nobili1, Alessandra Marengoni, Mauro Tettamanti, Francesco Salerno, Luca Pasina, Carlotta Franchi, Alfonso Iorio, Maura Marcucci, Salvatore Corrao, Giuseppe Licata, Pier Mannuccio Mannucci.   

Abstract

BACKGROUND: Although the association between multimorbidity and polypharmacy has been clearly documented, no study has analyzed whether or not specific combinations of diseases influence the prescription of polypharmacy in older persons. We assessed which clusters of diseases are associated with polypharmacy in acute-care elderly in-patients.
METHODS: This cross-sectional study was held in 38 Italian internal medicine and geriatric wards participating in the Registro Politerapie SIMI (REPOSI) study during 2008. The study sample included 1155 in-patients aged 65 years or older. Clusters of diseases, defined as two or more co-occurring specific chronic diseases, were identified using the odds ratio (OR) for the associations between pairs of diseases followed by cluster analysis. Polypharmacy was defined as the prescription of five or more different medications at hospital discharge. Logistic regression models were run to analyze the association between clusters of diseases and polypharmacy.
RESULTS: Among clusters of diseases, the highest mean number of drugs (>8) was found in patients affected by heart failure (HF) plus chronic obstructive pulmonary disease (COPD), HF plus chronic renal failure (CRF), COPD plus coronary heart disease (CHD), diabetes mellitus plus CRF, and diabetes mellitus plus CHD plus cerebrovascular disease (CVD). The strongest association between clusters of diseases and polypharmacy was found for diabetes mellitus plus CHD plus CVD, diabetes plus CHD, and HF plus atrial fibrillation (AF).
CONCLUSIONS: The observed knowledge of the relationship among co-occurring diseases and polypharmacy should help to identify and monitor older in-patients at risk of polypharmacy.
Copyright © 2011 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22075287     DOI: 10.1016/j.ejim.2011.08.029

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  44 in total

Review 1.  Routine deprescribing of chronic medications to combat polypharmacy.

Authors:  Doron Garfinkel; Birkan Ilhan; Gulistan Bahat
Journal:  Ther Adv Drug Saf       Date:  2015-12

Review 2.  Concerns about the use of new oral anticoagulants for stroke prevention in elderly patients with atrial fibrillation.

Authors:  Claudia Stöllberger; Josef Finsterer
Journal:  Drugs Aging       Date:  2013-12       Impact factor: 3.923

Review 3.  The Challenges of Treating Sciatica Pain in Older Adults.

Authors:  Manuela L Ferreira; Andrew McLachlan
Journal:  Drugs Aging       Date:  2016-11       Impact factor: 3.923

Review 4.  The Psychosocial Challenges and Care of Older Adults with Diabetes: "Can't Do What I Used To Do; Can't Be Who I Once Was".

Authors:  Elizabeth A Beverly; Marilyn D Ritholz; Chelsea Shepherd; Katie Weinger
Journal:  Curr Diab Rep       Date:  2016-06       Impact factor: 4.810

Review 5.  Acute bacterial skin and skin structure infections in internal medicine wards: old and new drugs.

Authors:  Marco Falcone; Ercole Concia; Massimo Giusti; Antonino Mazzone; Claudio Santini; Stefania Stefani; Francesco Violi
Journal:  Intern Emerg Med       Date:  2016-04-15       Impact factor: 3.397

Review 6.  Addressing Multimorbidity and Polypharmacy in Individuals With Atrial Fibrillation.

Authors:  Fahad Shaikh; Lachlan B Pasch; Phillip J Newton; Beata V Bajorek; Caleb Ferguson
Journal:  Curr Cardiol Rep       Date:  2018-03-24       Impact factor: 2.931

7.  Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: results from the REPOSI study.

Authors:  Luca Pasina; Codjo D Djade; Ugo Lucca; Alessandro Nobili; Mauro Tettamanti; Carlotta Franchi; Francesco Salerno; Salvatore Corrao; Alessandra Marengoni; Alfonso Iorio; Maura Marcucci; Francesco Violi; Pier Mannuccio Mannucci
Journal:  Drugs Aging       Date:  2013-02       Impact factor: 3.923

8.  Changes in drug prescribing to Italian community-dwelling elderly people: the EPIFARM-Elderly Project 2000-2010.

Authors:  Carlotta Franchi; Mauro Tettamanti; Luca Pasina; Codjo Djade Djignefa; Ida Fortino; Angela Bortolotti; Luca Merlino; Alessandro Nobili
Journal:  Eur J Clin Pharmacol       Date:  2014-01-08       Impact factor: 2.953

9.  Excessive polypharmacy and survival in polypathological patients.

Authors:  Jesús Díez-Manglano; Mercedes Giménez-López; Vanesa Garcés-Horna; María Sevil-Puras; Elena Castellar-Otín; Paloma González-García; Isabel Fiteni-Mera; Teresa Morlanes-Navarro
Journal:  Eur J Clin Pharmacol       Date:  2015-04-26       Impact factor: 2.953

10.  Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study.

Authors:  Valeria Raparelli; Marco Proietti; Carmelo Buttà; Paolo Di Giosia; Domenico Sirico; Paolo Gobbi; Salvatore Corrao; Giovanni Davì; Anna Rita Vestri; Francesco Perticone; Gino Roberto Corazza; Francesco Violi; Stefania Basili
Journal:  Intern Emerg Med       Date:  2014-07-03       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.